Compare Ares Capital Corporation (ARCC) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ares Capital Corporation vs Sana Biotechnology Inc — how do they compare? Ares Capital Corporation trades at $19.87 (market cap $14.34B), while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: Ares Capital Corporation is far larger — about 12.7× Sana Biotechnology Inc's market cap, and Ares Capital Corporation pays a 9.61% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| ARCC | SANA | |
|---|---|---|
Market Cap | $14.34B | $1.13B |
Sector | Financials | Health |
52-Week High | $22.68 | $5.92 |
52-Week Low | $17.45 | $2.68 |
Dividend Yield | 9.61% | — |
Enterprise Value | — | $1.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARCC trades at $19.87, down 0.55% with a bullish technical outlook supported by moving averages. The company reported $1.51B revenue and $1.30B net income for 2025, maintaining an 86.25% profit margin. Recent earnings show slight misses against expectations, but dividend coverage remains stable at 104% with a 9.9% yield. Analyst consensus is strongly bullish with 24 buy ratings and a $19.63 price target.
The stock presents income appeal with its high dividend yield and stable payout history, though recent earnings compression and rising non-accruals to 2.4% signal credit quality concerns. Private credit sector strain and potential rate cuts pose medium-term risks to net investment income, which is 71% variable-rate exposed.
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ares Capital Corporation
Ares Capital Corp is a United States-based closed-ended specialty finance company. Its investment objective is to generate both current income and capital appreciation through debt and equity investments. The company focuses on investing primarily in U.S. middle-market companies with investment opportunities as well as in larger companies. Its portfolio comprises of first lien senior secured loans, second lien senior secured loans, and mezzanine debt (subordinated unsecured loan), which may include equity components that are diversified by industry and sector. The company may invest in preferred and common equity investments to a lesser proportion. Its revenue mainly consists of interest and dividend income received from the investment made.
Read more on ARCC →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
